FDA Advisory Panel Reviews Multi-Cancer Blood Test
The screening tool for over 50 cancer types awaits final federal approval after a recent panel review.
Updated on Oct. 28, 2026 in Cancer
Live Poll
Would you use an expensive, non-diagnostic cancer screening test if its medical effectiveness remains unproven?
In September 2026, an FDA advisory panel reviewed the safety and effectiveness of the Galleri blood test, which screens for more than 50 types of cancer. While the test is currently pending federal approval, it has been available commercially since 2021 for adults ordering it through a primary care physician.
Why it matters
The test is designed to identify cancers in their earlier, more treatable stages before symptoms manifest. The recent panel review highlights the evolving regulatory discussion surrounding multi-cancer early detection, which currently remains outside standard screening guidelines.
An FDA advisory panel evaluated the Galleri blood test, resulting in a 10-0 vote for safety, a 7-2 vote that benefits exceed risks, and a 6-4 vote for effectiveness. The final decision on the test, which screens for over 50 cancer types, remains pending with federal regulators.
The players
FDA
The federal agency responsible for evaluating the safety and effectiveness of medical devices and diagnostics.
Dr. Victor van Berkel
A physician who participated in the September 2026 FDA advisory panel review of the cancer screening test.
The details
The Galleri test works by detecting cancer-specific patterns in cells shared across a wide range of tumor types. When the test yields a positive result, physicians must perform follow-up diagnostics such as MRIs, CT scans, mammograms, or colonoscopies to confirm the specific cancer type and location. It is not designed to replace standard screenings like Pap smears or traditional colonoscopies.
Timeline
2021: The Galleri test was commercially released.
September 2026: An FDA advisory panel reviewed the safety and effectiveness of the test.
Health Landscape
The Galleri test sits outside the current standard of care defined by United States Preventative Medicine Task Force guidelines. These existing benchmarks currently dictate the landscape for clinical cancer screening and insurance coverage for the American public.
Because the test requires an order from a primary care physician and costs $800 to $1,000 out-of-pocket, patients should discuss the limitations of this screen with their doctor. It is critical to understand that this blood test is not a replacement for established screenings like mammograms or colonoscopies.
The takeaway
The Galleri test remains a screening tool that operates independently of standard preventative guidelines. Always consult your primary care physician to determine if additional testing is appropriate for your specific health history and risk profile.
Further reading
For more on the current methods used to screen for malignancies, visit our Cancer resource hub.
Source note: This article includes information reported by The Courier-Journal.
Live Poll
Would you use an expensive, non-diagnostic cancer screening test if its medical effectiveness remains unproven?
